# 1. Financial Performance ## A. Key Figures * **Consolidated Revenue:** **₹188 Cr** (Qo Jun 2025) (+20.4% YoY) * EBITDA Margin: 39.1% (Qo Jun 2025) * PAT Margin: 20.4% (Qo Jun 2025) * **Cash Position:** **₹270 Cr** (as of 30 Jun 2025) · **₹220 Cr** net cash after capital creditors * **CAPEX Guidance (FY26):** **₹150–155 Cr** (new centers) · **2%–3%** of topline (replacement) ## B. Revenue Growth * **Resilient Volume-Driven Growth:** Revenue growth sustained by **17% test volume increase** and **favorable test mix**, with Hyderabad returning to double-digit expansion. * **Stable Sequential Trends:** Average daily revenue showed consistent sequential improvement from April to June, overcoming minor early-April volatility. * **Track Record of Outperformance:** Company has delivered **strong double-digit growth** in 7–8 of the last 8 quarters, underscoring durable operating momentum. ## C. EBITDA & PAT Margins * **Margins Held Steady Amid Expansion:** EBITDA margin maintained at 1% despite new hub launches, aided by **strong operating leverage** and better-than-expected cost absorption. * **Gross Margin Expansion Surprise:** Margins improved despite input cost pressures and no broad price increases, signaling operational efficiency gains. ## D. Balance Sheet Strength * **Robust Liquidity Supports Growth Strategy:** Strong cash position enables continued **organic expansion** and provides optionality for **strategic inorganic opportunities**. * **IndAS Impact Quantified:** Q1 FY26 IndAS adjustment amounts to **₹8 Cr (1%)**, with interest and depreciation contributing **₹92 Cr** and **₹95 Cr**, respectively. --- # 2. Volume & Footfall Trends ## A. Key Figures * **Test Volume Growth:** **13–14%** (old centers) ## B. Volume Drivers & Market Shift * **Volume-Driven Growth:** Revenue expansion primarily fueled by **strong test volume and footfall growth**, not pricing, underscoring organic demand strength. * **Market Consolidation:** Accelerating patient inflows reflect **growing brand strength** and continued **shift from unorganized players** to organized diagnostics. ## C. Unit Economics & Center Performance * **Record Revenue per Patient:** Highest level in over 20 quarters, driven by **deepening customer loyalty** and trust in established centers. * **Resilient Center Productivity:** Revenue per center remains robust despite new center ramp-ups and absence of seasonal tailwinds, signaling operational discipline. --- # 3. Center Expansion & Capacity ## A. Key Figures * **New Hubs Commissioned:** **5** in Q1 FY'26 (of **10** annual target) · **3** new hubs in Q2 FY'26 planned · **2** additional West Bengal hubs in H2 FY'26 * **Lease Liabilities:** **~₹1 Cr** increase due to new hub additions * **Breakeven Performance:** New hubs breakeven in **2–3 quarters** · **Nizamabad hub** achieved breakeven in **2 quarters** · breakeven at **~33% capacity utilization** * **Revenue per Spoke:** **₹2–6.5 Cr** annually (location-dependent) ## B. New Hub Performance * **Accelerated Rollout:** Robust execution on expansion plan with five hubs and one spoke commissioned in Q1, supporting full-year target of 10 hubs. * **Limited Initial Drag:** New Kolkata and Kalyani Nagar hubs had only 1–5 months of operations in Q1, minimizing near-term P&L impact. * **Scalable Model:** Rising lease liabilities reflect ongoing asset-light expansion, fully aligned with growth trajectory. ## C. Breakeven Timeline * **Faster-than-Expected Payback:** All new centers on track to breakeven within 12 months, with one Bangalore hub ahead of schedule and Nizamabad achieving breakeven in just two quarters. * **Efficient Utilization:** Breakeven achieved at low capacity thresholds (~33%), demonstrating strong demand absorption and operational discipline. * **No Sustained Losses:** Initial financial drag from new centers is minimal (1%–2%) and offset by efficiency gains, confirming capital efficiency. ## D. Capacity Constraints * **Localized Bottlenecks:** Most centers operate without constraints; Pune faces temporary pressure post-PH acquisition, but new hubs are being deployed to alleviate strain. * **Equipment-Driven Limits:** Capacity ceilings are site-specific, often tied to radiology infrastructure rather than physical space. * **Revenue Variability:** Wide range in spoke-level revenue reflects market maturity differences, limiting one-size-fits-all capacity benchmarks. --- # 4. Service & Segment Mix ## A. Key Figures * **Radiology Revenue Mix:** **39%** of total revenue (highest to date) * **Wellness Segment Share:** **14%–15%** of annual revenue (up from 11%–12%) * Price Impact on Growth: Only 1.5% of revenue growth attributed to price increases * Home Collection Revenue: Grew to 3.2% to 3.3% of total revenue ## B. Radiology vs Pathology * **Radiology Drives Revenue & Margin Upside:** Record contribution from radiology—driven by advanced imaging and new hubs—lifted revenue per patient and boosted margins due to **lower material costs** and higher gross margins. * **Sustained Mix Shift, But Range-Bound Outlook:** Despite faster growth in radiology, structural constraints from hub-and-spoke expansion limit quarterly mix shifts to **1%–2%**, capping near-term volatility. * **Favorable Test Mix, Not Pricing, Fuels Growth:** Volume and service mix dynamics—not price hikes—are the primary growth drivers, with pricing contributing minimally to top-line expansion. ## C. Wellness Segment Share * **Wellness Share Stabilizing at Higher Base:** After sustained growth, wellness now contributes a stable **14%–15%** of annual revenue, supported by corporate outreach and digital channels, though absolute scale remains small. * **Low Incremental Costs Enhance EBITDA Resilience:** Despite **lower gross margins**, wellness has minimal EBITDA drag due to **~70% fixed cost structure**, making additional volume highly efficient at the branch level. * **Recent Margin Benefit from Volume Mix:** A slight decline in wellness testing volume versus prior quarter provided a modest tailwind to gross margins. ## D. Home Collection Growth * **Home Collection Penetration Improving:** Channel now represents **2–3%** of revenue, reflecting stronger patient access and service convenience, though still early in scale-up phase. --- # 5. Geographic Expansion ## A. Key Figures * **Revenue Contribution:** **~70%** from Hyderabad * **Ramp-up Growth Rate:** **70%–80%** in Eastern India (West Bengal) * Revenue Target: ₹50–100 Cr expected from Eastern India via expansion in next 2-3 years ## B. Hyderabad Market Share * **Dominant Home Base:** Hyderabad remains the core revenue driver, with sustained market share gains fueled by the company’s integrated B2C model and dense network. * **Structural Advantage:** Operational density enables consistent outperformance in a competitive but stable landscape, capturing share primarily from the unorganized sector. ## C. Eastern India Ramp-up * **High-Growth Early-Stage Expansion:** Eastern India, particularly West Bengal, is scaling rapidly with strong ramp-up momentum, supported by a hub-and-spoke strategy. * **Strategic Scaling Plan:** Expansion in FY27 targeting Bangalore, Kolkata, and Pune; multiple centers now active, with new hubs foundational to long-term scaling. * **Acquisition Readiness:** Management is actively evaluating inorganic opportunities through partners like JM Financial, prioritizing asset quality and integration fit. ## D. New City Performance * **Outperformance in New Markets:** Recent entries in Pune, Kolkata, and Bangalore are gaining traction ahead of expectations, with no drag on margins. * **Pune Momentum Building:** Post-acquisition capacity constraints are being addressed via new hubs—two added recently—with revenue improving over the past five months. * **Network Expansion:** Added **four centers** across Pune, Kolkata, and Bangalore in the quarter, reinforcing commitment to geographic diversification. --- # 6. Pricing & Input Cost Risks ## A. Key Figures * **Volume Growth (Old Centers):** **11%** * **Revenue per Test Growth Contribution from Pricing:** **1% to 5%** ## B. Selective Price Hikes * **Targeted Pricing Discipline:** Revenue growth outpaced volume in mature centers, indicating **modest price realization** from selective hikes on specific tests in cost-impacted geographies. * **Stable Pricing Outlook:** No price increases planned for current fiscal; adjustments typically reserved for Q1, with B2C model maintaining high pricing stability. * **Cost-Driven Triggers:** Price actions limited to tests facing input cost pressures, reflecting a defensive and surgical approach to margin preservation. ## C. Input Cost Pressures * **Risk-Sharing in Routine Testing:** Reagent rental model insulates margins in routine labs by shifting equipment maintenance burden to OEMs. * **CAPEX-Led Specialized Testing:** Owned equipment for specialized testing brings higher operational cost responsibility, creating potential maintenance cost volatility. ## D. Monsoon Demand Impact * **Seasonal Delay in Q2:** Monsoon-related testing demand, typically a volume driver, has been **slightly delayed** in key regions, pushing acute care volume ramp into later weeks of the quarter. --- # 7. Guidance & Outlook ## A. Key Figures * **Revenue Growth Guidance:** **15%** (+13% volume, +2–5% pricing) · **15%+ long-term target** * EBITDA Margin Guidance: 38–38.5% full-year target (–100–150 bps impact from near-term hub launches) ## B. Revenue Growth Forecast * **Sustained Double-Digit Momentum:** Leadership position in a rapidly expanding Hyderabad market enables confidence in outperforming guidance, supported by strong patient trust and operational scale. * **Growth Drivers:** Volume expansion remains the primary engine, with majority contribution from existing centers and incremental uplift from new center ramp-up. ## C. FY26 Hub Addition Plan * **Execution on Track:** Full-year plan to launch 10 new hubs remains unchanged, reinforcing commitment to geographic and capacity expansion. ## D. Margin Guidance * **Margin Resilience:** Despite dilutive impact from **five upcoming hub openings**, EBITDA margins are expected to hold within guided range, reflecting disciplined cost management. * **Selective Disclosure:** Management refrained from disclosing margin profiles by center maturity due to competitive sensitivity, underscoring strategic caution.